Beyond Weight Loss: GLP-1 Cardiovascular and Kidney Data
GLP-1 evidence extends beyond weight loss: SELECT showed semaglutide cut cardiovascular events ~20%, and FLOW showed it slowed kidney disease progression in type 2 diabetes. These benefits apply to the approved products, not compounded versions.
- SELECT: semaglutide cut major cardiovascular events ~20% (CVD, no diabetes).
- FLOW: semaglutide slowed chronic kidney disease progression in type 2 diabetes.
- SUSTAIN and other trials support cardiovascular benefit in diabetes.
- These organ-protection findings apply to approved products only.
The cardiovascular evidence
The most prominent non-weight benefit is cardiovascular. The SELECT trial showed semaglutide 2.4mg reduced major adverse cardiovascular events by about 20% in adults with cardiovascular disease and overweight or obesity, without diabetes.
Earlier trials in people with type 2 diabetes, including the SUSTAIN cardiovascular outcomes program, also demonstrated cardiovascular benefit. Together these established semaglutide as more than a weight or glucose drug.
The benefit appears only partly explained by weight loss, suggesting direct cardiovascular effects.
The kidney evidence
The FLOW trial studied semaglutide in people with type 2 diabetes and chronic kidney disease and found it slowed the progression of kidney disease and reduced kidney-related events. This is a meaningful finding, because kidney disease is a major complication of diabetes with few effective drug options.
The kidney benefit adds to the cardiovascular data, painting a picture of organ protection that extends beyond the drug's effect on weight and glucose.
As with the cardiovascular data, this evidence is for the approved product in the studied population.
| Trial | Population | Finding |
|---|---|---|
| SELECT | CVD + overweight/obesity, no diabetes | ~20% fewer cardiac events |
| FLOW | Type 2 diabetes + CKD | Slowed kidney disease |
| SUSTAIN CVOT | Type 2 diabetes | Cardiovascular benefit |
How to interpret organ-protection data
These findings are important but specific. Each applies to a defined population: SELECT to CVD patients with overweight/obesity without diabetes, FLOW to diabetes patients with kidney disease. The benefits are most directly applicable to people resembling those groups.
It is not valid to assume every person taking a GLP-1 gets the same cardiovascular or kidney protection, nor that the benefits transfer to tirzepatide automatically, though tirzepatide has its own outcomes trials underway.
Relative risk reductions also translate to smaller absolute differences, though across high-risk populations the events prevented are substantial.
Why compounded products are excluded
Every one of these organ-protection findings was demonstrated with an FDA-approved product manufactured to a defined standard. Compounded semaglutide has no cardiovascular or kidney outcome data of its own.
Assuming the SELECT or FLOW benefits transfer to a compounded formulation is not evidence-based. The molecule may match, but the outcome evidence attaches to the studied product.
For a patient whose goal includes cardiovascular or kidney protection, this is a specific reason to discuss the approved product with a clinician.
| Applies to | Does not apply to |
|---|---|
| Approved semaglutide products | Compounded semaglutide |
| Studied populations | Everyone automatically |
The bottom line
GLP-1 benefits extend beyond weight loss: semaglutide reduced cardiovascular events (~20% in SELECT) and slowed kidney disease progression (FLOW), with additional diabetes cardiovascular data.
These organ-protection findings apply to approved products in defined populations, not to compounded versions or automatically to everyone. Tirzepatide's own outcome trials are ongoing.
If organ protection is a goal, that is a reason to discuss the approved product with your clinician.
Frequently asked questions
What cardiovascular benefit does semaglutide have?
In SELECT, semaglutide 2.4mg reduced major cardiovascular events by about 20% in adults with cardiovascular disease and overweight or obesity, without diabetes.
Does semaglutide protect the kidneys?
The FLOW trial showed semaglutide slowed chronic kidney disease progression in people with type 2 diabetes and kidney disease.
Do these benefits apply to compounded semaglutide?
No. They were demonstrated with approved products. Compounded semaglutide has no cardiovascular or kidney outcome data.
Does tirzepatide have the same organ data?
Tirzepatide has its own outcomes trials underway. The semaglutide findings do not automatically transfer to it.
Sources
- FDA — drug labels and compounding status (Drugs@FDA, fda.gov/drugs/human-drug-compounding).
- NEJM — STEP, SELECT, SURMOUNT, SURPASS, SUSTAIN, FLOW trial publications.
- ClinicalTrials.gov and prescribing information.
- Evidence policy: evidence policy.
The numbers behind this page
Checking the figures in this entry
Every price quoted in this entry comes from the programme's own pricing page and carries the date it was captured. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Where this sits in the market
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Questions this page answers
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.
What is the cheapest verified GLP-1 programme?
NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.